title: Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration.
abstract: Seventy intraperitoneal administrations of doxorubicin were performed in 12 patients with malignant disease in the abdominopelvic space. Peritoneal and hematologic drug levels were measured by fluorimetric assay. A first-order decline in the peritoneal level was determined (T 1/2 96 +/- 18 min), with a mean drug absorption of 84% in 4 h (range 40-96%) and a mean ratio of a peak dialysate/peak serum level of 111 (range 12-390). Gastrointestinal toxicity was common and peritoneal phlogosis occurred twice. The doxorubicin level and the time of peritoneal exposure seem to be critical factors for major local toxicity. At a moderate concentration doxorubicin can be intraperitoneally administered, but its usefulness is probably confined to patients with minimal abdominal disease.
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D000042:Absorption; D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007700:Kinetics; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D013997:Time Factors
chemical_list: D004317:Doxorubicin